Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries

Invasive mucormycosis (IM) in patients with acute leukemia and allogeneic stem cell transplant (allo-SCT) recipients treated with antifungal monotherapy is associated with high mortality rates of 44–49%.[1][1]–[3][2] Among the available antifungals, amphotericin B (AmB) formulations and

[1]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  P. Hamal,et al.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  J. Perfect,et al.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. , 2011, The Journal of antimicrobial chemotherapy.

[4]  K. Gupta,et al.  Rhino-Orbital-Cerebral Zygomycosis in Solid Organ Transplant Recipients , 2010, Transplantation.

[5]  B. Spellberg,et al.  The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. , 2010, The Journal of antimicrobial chemotherapy.

[6]  A. Simon,et al.  Forty-one recent cases of invasive zygomycosis from a global clinical registry. , 2009, The Journal of antimicrobial chemotherapy.

[7]  B. Spellberg,et al.  Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.

[8]  J. Guarro,et al.  Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae , 2008, Antimicrobial Agents and Chemotherapy.

[9]  M. Dierich,et al.  Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[10]  M. Rinaldi,et al.  In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[11]  D. Loebenberg,et al.  In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.

[12]  D. Kontoyiannis,et al.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Maniatis,et al.  In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus , 2008 .